ClinicalTrials.gg
Sign In
RecruitingNCT02830308Updated Sep 28, 2026

Evaluation of Adults With Endocrine and Metabolic-Related Conditions

An observational study in Endocrine Diseases, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Observational

From the registry’s dates

  • Started Jul 2016; still recruiting 10 years 4 months later.
Updated Sep 28, 2026Study contact changedGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,250
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Background:

There are many endocrine and metabolic-related conditions. Two well-known disorders include diabetes and thyroid disease. Some of these diseases are caused by a change in genes. Researchers want to identify the genes involved in these disorders. They hope this will help them learn more about these diseases.

Objectives:

To learn more about conditions that affect the hormone-secreting glands (endocrine glands) in adults. To train doctors to diagnose and treat people with endocrine or metabolic conditions.

Eligibility:

Adults age 18 years and older with a known or suspected endocrine disorder.

Relatives ages 18 years and older.

Doctors will review all requests and available medical records to determine final eligibility for the protocol.

Design:

Participants will have a medical history and physical exam.

Most participants will have 1 visit, and may have follow up visits if necessary. They may have tests, surgery, or other procedures to help diagnose or treat their condition. These could include:

  • Blood, urine, and saliva tests
  • Imaging tests. These may include X-ray, ultrasound, or scans.
  • Sleep study
  • Medical photographs
  • Visits with other specialists at NIH

Participants will provide blood, urine, saliva, or tissue samples. Some of these samples may be stored in the freezer for future studies.

Participants may be asked to participate in genetic testing. They will give a blood or saliva sample for this.

Read the detailed description

This is an observational protocol designed to collect data from adult subjects with known or suspected endocrine or metabolic disorders.

OBJECTIVE: The overall purpose of endocrine evaluations under this protocol is to increase knowledge of endocrine or metabolic diseases. Adults with known or suspected endocrine or metabolic-related condition(s) may be evaluated under this protocol for:

  1. Collection of data for endocrine related conditions (case reports, case series)
  2. Collection of data for future research
  3. Collection of samples, including leftover samples from clinically indicated tests, for future research (including genomics)

METHODS: Patients will undergo a history and physical exam, anthropometrics, vital signs and endocrine laboratory studies.

02

Conditions studied

  • Endocrine Diseases

Keywords

  • Hormones
  • Endocrine
  • Hypercortisolism
  • Bone
  • Hypothalamic-Pituitary Dysfunction
  • Natural History
03

In context

Endocrine System Diseases

322 studies on the registry are indexed under Endocrine System Diseases; 51 are open to participants now.

This study's planned enrollment of 1,250 is above the median of 134 across 88 observational studies indexed under Endocrine System Diseases.

Browse Endocrine System Diseases studies →

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is the lead sponsor of 538 studies on the registry; 55 are open to participants now.

Of its 80 completed or terminated interventional studies of FDA-regulated products, 51 (64%) have results posted.

Browse National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Primary Clinical

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with known or suspected endocrine disorder age 18 years and older are eligible for this protocol. Protocol investigators will make the actual selection of subjects most appropriate for clinical evaluation.
  • Relatives ages 18 years and older may be enrolled if clinically indicated for the diagnosis of a proband.

Exclusion criteria

EXCLUSION CRITERIA:

  • Anyone under the age of 18 years old
  • Any medical, physical, psychiatric, or social conditions, which, in the opinion of the investigators, would make participation in this protocol not in the best interest of the subject. Subjects who are critically ill, unstable, or with severe organ failure that may affect/limit the endocrine evaluation and place unsustainable demands on Clinical Center or NIDDK resources.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,250 participants (estimated)

Groups and cohorts

  • Adults with known or suspected endocrine or metabolic dissorde

    Adults with known or suspected endocrine or metabolic dissorders

06

What researchers measure

Primary outcomes

  1. Recruit a diverse population of adult subjects with a known or suspected endocrine or metabolic disorder in order to provide NIDDK investigators and trainees with hands-on experience related to the diagnosis, management, treatment, and follow-up...

    The overall purpose of endocrine evaluations under this protocol is to support our clinical training and research missions.

    Time frame: 12/31/2036

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
08

References and documents

Publications

  • Abd-Elmoniem KZ, Edwan JH, Dietsche KB, Villalobos-Perez A, Shams N, Matta J, Baumgarten L, Qaddumi WN, Dixon SA, Chowdhury A, Stagliano M, Mabundo L, Wentzel A, Hadigan C, Gharib AM, Chung ST. Endothelial Dysfunction in Youth-Onset Type 2 Diabetes: A Clinical Translational Study. Circ Res. 2024 Aug 30;135(6):639-650. doi: 10.1161/CIRCRESAHA.124.324272. Epub 2024 Jul 29. PubMed 39069898 ↗

Individual participant data

Plan to share: Yes — De-identified results from clinical trials will be posted on cctrials.gov

Supporting information: Study protocol

Time frame: Not otherwise specified in protocol.

Access criteria: Only investigators will have access to the data. Publications will not include subject names, nor will they contain personal identifying information. De-identified results from clinical trials will be posted on cctrials.gov

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2016 (actual). Primary completion is estimated for Dec 2029, 161 months after the start.

Of 32 observational studies under Endocrine System Diseases, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 339. This study's planned 161 months is above that.

Endocrine System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2016
First posted
Jul 12, 2016
StartActual
Jul 9, 2016
Primary completionEst.
Dec 20, 2029
CompletionEst.
Dec 31, 2029
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact's phone or email changed: m•••@nih.gov→d•••@nih.gov. See the current contact
Sep 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • National Institutes of Health Clinical Center · Bethesda, United StatesContact added d•••@nih.gov
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Contact Study contact's phone or email changed: m•••@nih.gov→d•••@nih.gov. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • National Institutes of Health Clinical Center · Bethesda, United StatesContact added d•••@nih.gov
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02830308
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Responsible party
Sponsor
First posted
Jul 12, 2016
Start date
Jul 9, 2016
Primary completion
Dec 20, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 28, 2026

Study contacts

Marissa F Lightbourne, M.D.
Contact
diabetesandendocrineclinic@nih.gov
(301) 827-0033
Marissa F Lightbourne, M.D.
principal investigator · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Endocrine System Diseases →

Other studies from this sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) →

Start the discussion